Welcome to our dedicated page for Ironwood Pharmaceuticals news (Ticker: IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announces the immediate appointment of Jay P. Shepard to its Board of Directors. Shepard, a seasoned leader with nearly three decades of experience, will also serve on the Audit Committee, expanding the board to 11 members, nine of whom are independent. The company aims to leverage Shepard's expertise to enhance its mission in the treatment of gastrointestinal (GI) diseases. Shepard's background includes leadership roles at several clinical-stage companies, emphasizing his suitability for this position.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will engage in a virtual fireside chat during the 29th Annual Credit Suisse Healthcare Conference on November 11, 2020, at 3:30 p.m. ET. Interested listeners can access the live webcast via the Investors section of Ironwood's website, starting 15 minutes before the event. A replay will be available for 14 days post-conference. Ironwood focuses on developing treatments for gastrointestinal diseases and is known for its linaclotide product, a leader in the U.S. market for IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) reported strong financial results for Q3 2020, driven by a 10% year-over-year increase in LINZESS net sales, totaling $241 million. The company achieved a GAAP net income of $34.4 million ($0.22 per share), significantly up from $20.6 million the previous year. However, setbacks in its pipeline prompted the termination of IW-3718 development, leading to a planned 100-employee reduction. Ironwood expects cost savings of $95 million from this restructuring. The company also raised its 2020 revenue guidance to $370-$385 million.
Ironwood Pharmaceuticals (NASDAQ: IRWD) has appointed Alexander Denner, Ph.D., to its Board of Directors effective November 9, 2020. With Dr. Denner's appointment, the Board will consist of 10 directors, eight of whom are independent. Julie McHugh, Board Chair, emphasized Dr. Denner's extensive healthcare investment experience as a valuable asset for advancing gastrointestinal medicines and enhancing shareholder value. Dr. Denner is the founding partner of Sarissa Capital Management LP and has a notable history of leadership in healthcare companies.
Ironwood Pharmaceuticals (NASDAQ: IRWD) will host its third quarter 2020 investor update conference call on November 5, 2020, at 4:30 p.m. Eastern Time. Participants can dial (833) 350-1432 (U.S. and Canada) or (647) 689-6932 (international) to join the call using conference ID 2794527. A replay will be available starting the same day at 7:30 p.m. ET through November 19 at (800) 585-8367 (U.S. and Canada). Ironwood is focused on developing therapies for gastrointestinal diseases, notably linaclotide for IBS-C and CIC.
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced disappointing results from its Phase III trial IW-3718-302 for IW-3718, which failed to meet primary endpoints for treating refractory gastroesophageal reflux disease (GERD). Following this, Ironwood will discontinue IW-3718's development and halt enrollment in another related trial. The company plans to reduce its workforce by 35%, saving over $95 million, but incur one-time costs of up to $12 million linked to the layoffs. Ironwood remains focused on maximizing LINZESS, its leading GI medication.